Alnylam Pharmaceuticals Inc Sustainability Reports

Alnylam Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). The company develops targeted medicines for rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 529900S3ZI14OWRJII50

FIGI: BBG001S7FTC8

15 reports from 2007 to 2025

• Alnylam Pharmaceuticals Inc 2025 Annual Report
• Alnylam Pharmaceuticals Inc 2025 Corporate Responsibility Report
• Alnylam Pharmaceuticals Inc 2024 Corporate Responsibility Report
• Alnylam Pharmaceuticals Inc 2023 Annual Report on Form 10-K
• Alnylam Pharmaceuticals Inc 2022 Annual Report on Form 10-K